Published in J Am Acad Dermatol on March 01, 2005
Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol (2009) 1.91
Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol (2014) 1.57
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol (2012) 1.21
Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol (2016) 0.99
Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol (2014) 0.91
Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J (2014) 0.87
Periodontal disease and risk of psoriasis among nurses in the United States. Acta Odontol Scand (2013) 0.83
Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. PLoS One (2012) 0.79
Apprehension of the disease by patients suffering from psoriasis. Postepy Dermatol Alergol (2014) 0.78
Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence (2016) 0.78
Treatment Satisfaction Among Patients with Moderate-to-severe Psoriasis. J Clin Aesthet Dermatol (2015) 0.77
Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2009) 0.76
Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis. Sci Rep (2016) 0.76
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid (2010) 0.75
The challenges of assessing patients' medication beliefs: a qualitative study. BMC Health Serv Res (2017) 0.75
Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics (2007) 0.75
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. Clinicoecon Outcomes Res (2015) 0.75
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice. J Int Med Res (2016) 0.75
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42
Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55
Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med (2003) 5.09
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc (2004) 3.40
Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol (2003) 3.22
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol (2005) 3.11
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Adherence, the fourth dimension in the geometry of dermatological treatment. Arch Dermatol (2009) 2.91
In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch Dermatol (2002) 2.75
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ (2002) 2.46
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol (2011) 2.36
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol (2005) 2.26
Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol (2011) 2.22
Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol (2007) 2.19
Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18
Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol (2003) 1.95
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87
Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes. J Diabetes Complications (2012) 1.84
Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83
Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol (2004) 1.81
Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80
Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med (2013) 1.79
Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol (2007) 1.76
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol (2007) 1.75
Hemoglobin A1c predicts healing rate in diabetic wounds. J Invest Dermatol (2011) 1.73
Optical recording of neuronal activity with a genetically-encoded calcium indicator in anesthetized and freely moving mice. Front Neural Circuits (2010) 1.71
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol (2013) 1.64
Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat (2006) 1.64
The risk of lymphoma in patients with psoriasis. J Invest Dermatol (2006) 1.62
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57
Drug samples in dermatology: special considerations and recommendations for the future. J Am Acad Dermatol (2010) 1.55
Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol (2010) 1.53
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53
Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol (2008) 1.52
Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol (2007) 1.51
A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. Arch Dermatol (2010) 1.50
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol (2007) 1.50
UV light abuse as a substance-related disorder: clinical implications. Arch Dermatol (2008) 1.48
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol (2004) 1.45
Represcription of penicillin after allergic-like events. J Allergy Clin Immunol (2004) 1.44
Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol (2011) 1.44
Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol (2006) 1.44
Eyecup scope--optical recordings of light stimulus-evoked fluorescence signals in the retina. Pflugers Arch (2008) 1.43
Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs (2004) 1.43
Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol (2003) 1.43
Dermatosis neglecta: a series of case reports and review of other dirty-appearing dermatoses. Dermatol Online J (2006) 1.42
Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol (2005) 1.42
Trends in Mohs surgery from 1995 to 2010: an analysis of nationally representative data. Dermatol Surg (2015) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat (2006) 1.40
Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol (2006) 1.40
Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol (2006) 1.40
Where did current academic dermatologists train? J Am Acad Dermatol (2010) 1.39
Increase in procedures performed at dermatology office visits from 1995 to 2001. Dermatol Surg (2005) 1.39
Phototherapy trends in dermatology. J Dermatolog Treat (2013) 1.38
Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol (2012) 1.37
Use of electronic medical records differs by specialty and office settings. J Am Med Inform Assoc (2013) 1.34
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol (2007) 1.34
Quality of life in patients with psoriasis. Health Qual Life Outcomes (2006) 1.31
Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol (2003) 1.28
Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis (2002) 1.27
The safety of liposuction: results of a national survey. Dermatol Surg (2002) 1.25
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24
Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics (2009) 1.24
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22